Cassava Sciences, Inc. (SAVA:NASDAQ) Annual Reports & Investor Relations Material

Overview

Austin-based biotech firm Cassava Sciences, Inc. is focused on developing innovative drugs to combat neurodegenerative diseases, with its lead product candidate being the promising small molecule drug, simufilam. The drug has emerged as a standout candidate with the completion of its Phase 2b clinical trial. Additionally, the company is also working on an investigational diagnostic product, SavaDx, which uses blood-based biomarkers to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc., and underwent a name change in March of last year. The pioneering company was established in 1998, and has since remained committed to its mission to advance the treatment of neurodegenerative diseases.

Frequently Asked Questions

What is Cassava Sciences, Inc.'s ticker?

Cassava Sciences, Inc.'s ticker is SAVA

What exchange is Cassava Sciences, Inc. traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Cassava Sciences, Inc.'s headquarters?

They are based in Austin, Texas

How many employees does Cassava Sciences, Inc. have?

There are 1-10 employees working at Cassava Sciences, Inc.

What is Cassava Sciences, Inc.'s website?

It is https://www.cassavasciences.com/

What type of sector is Cassava Sciences, Inc.?

Cassava Sciences, Inc. is in the Healthcare sector

What type of industry is Cassava Sciences, Inc.?

Cassava Sciences, Inc. is in the Biotechnology industry

Who are Cassava Sciences, Inc.'s peers and competitors?

The following five companies are Cassava Sciences, Inc.'s industry peers:

- Synlogic

- Actinogen Medical

- BioSpecifics Technologies Corp.

- Acceleron Pharma Inc.

- Adaptive Biotechnologies